Bystander Effect of HSV-TK/GCV Gene Therapy in Murine Neuroblastoma.
- Author:
Eun Jung SHIM
1
;
Se Ryoung KIM
;
Eun Hae PARK
;
Hyun Sang CHO
;
Jae Kook CHA
;
Hae Ran LEE
Author Information
1. Department of Pediatrics, College of Medicine, Hallym University, Seoul, Korea. hscho@hallym.or.kr
- Publication Type:In Vitro ; Original Article
- Keywords:
Bystander effect;
HSV-TK;
Neuroblastoma
- MeSH:
Animals;
Bystander Effect*;
Cell Line;
Cell Survival;
Genetic Therapy*;
Mice;
Neuroblastoma*;
Survival Rate
- From:Journal of the Korean Pediatric Society
2001;44(11):1249-1253
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To demonstrate the bystander effect in murine neuroblastoma model which transduced with HSV-TK gene in vitro and in vivo. METHODS: The LNC/TK vector was transfered in vitro into the neuro-2a cells, murine neuroblastoma cell line. Variable mixed populations of neuro-2a cells consisting of HSV-TK+ or HSV-TK- were plated into culture plates and treated with GCV for another 4 days. Surviving cells were counted and cell viability was determinated. For investigating the in vivo bystander effect, variable mixed populations of neuro-2a cells consisting of HSV-TK+ and HSV-TK- were inoculated into A/J mice. The tumor size was measured following injection of GCV for 7 days. RESULTS: The survival rate of the 100% neuro-2a/TK group was 90%, 25%, 5% and 0%, of 50% neuro-2a/TK group was 92%, 30%, 10% and 0%, and of the 10% neuro-2a/TK group was 95%, 40%, 15% and 5%. But, the survival rate of 0% neuro-2a/TK group was 120%, 150%, 180% and 220% on days 1, 2, 3, and 4 respectively. In the 100% and 50% neuro-2a/TK groups, tumor had disappeared following administration of GCV and in 10% neuro-2a/TK group, tumor size was not increased during GCV treatment. In 0% neuro-2a/TK group, tumor size increased during administration of GCV and all mice died after 6 weeks. CONCLUSIONS: We demonstrated the bystander effect in a murine neuroblastoma model which transduced with HSV-TK gene in vitro and in vivo. These results suggest that HSV-TK/GCV gene therapy may be useful for treatment of neuroblastoma.
